



Grant Number: 5U01CA033193-31

Principal Investigator(s):
Kurt Straif

Project Title: Evaluation of Carcinogenic Risks to Humans

INTERNATIONAL AGENCY-RES CANCER
150 COURS ALBERT THOMAS
F-69372 LYON CEDEX 08, FRANCE,
FRANCE

Award e-mailed to: igo@iarc.fr

Budget Period: 09/01/2012 – 08/31/2013

Project Period: 09/01/1985 – 08/31/2015

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$833,601 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to INTERNATIONAL AGENCY FOR RES ON CANCER in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number U01CA033193. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with 42 CFR Part 50 Subpart F. Subsequent to the compliance date of the 2011 revised FCOI regulation (i.e., on or before August 24, 2012), Awardees must be in compliance with all aspects of the 2011 revised regulation; until then, Awardees must comply with the 1995 regulation. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Alice Chi Wong
Grants Management Officer
NATIONAL CANCER INSTITUTE

Additional information follows

SECTION I – AWARD DATA – 5U01CA033193-31

Award Calculation (U.S. Dollars)

Salaries and Wages	\$392,840
Fringe Benefits	\$130,949
Consultant Services	\$42,091
Travel Costs	\$2,271
Other Costs	\$149,852

Federal Direct Costs	\$718,003
Federal F&A Costs	\$115,598
Approved Budget	\$833,601
Federal Share	\$833,601
TOTAL FEDERAL AWARD AMOUNT	\$833,601

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$833,601

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
31	\$833,601	\$833,601
32	(b)(5)	
33		

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Number: 93.393
EIN: 1900210016A1
Document Number: UCA033193G
Fiscal Year: 2012

IC	CAN	2012	2013	2014
CA	8479565	\$833,601	(b) (5)	

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: A3CE / OC: 414P / Processed: CHIA01 09/21/2012

SECTION II – PAYMENT/HOTLINE INFORMATION – 5U01CA033193-31

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 5U01CA033193-31

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at 'http://grants.nih.gov/grants/policy/awardconditions.htm' for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

Treatment of Program Income:
Additional Costs

SECTION IV – CA Special Terms and Conditions – 5U01CA033193-31

REQUIREMENT: This award is issued as a cooperative agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the Terms and Conditions of Award below, which are hereby incorporated by reference as special terms and conditions of this award.

These special Terms and Conditions of Award are in addition to and not in lieu of otherwise applicable OMB administrative guidelines, Federal Regulations, including HHS Grant Administration Regulations at 42 CFR Part 52, 45 CFR Parts 74 and 92, and other HHS, PHS, and NIH Grant Administration policy statements.

Collaborative Terms of Award

Nature of Collaboration with NCI Staff

NCI has certain responsibilities in terms of this cooperative agreement which involve assistance, information support, and scientific collaboration.

1. Scientific Resource

Since the monographs on each chemical which appear in the columns published by IARC are fundamentally an international information resource and data bank on carcinogenesis and evaluation of qualitative risk of chemicals to human, NCI, in an assistance and cooperative role, provides information and data which assist IARC staff in the preparation of certain sections of the final monograph (Sections 1.1 to 2.3). Sections 3.1 to 4.3 are developed by the Working Groups which consist of international scientists who review all these documents at the time of the meetings (3 per year) in Lyon, France. The National Cancer Institute, through arrangements with a contractor will provide such assistance.

2. Planning for Meetings of the Working Group

The IARC project is one of international support with NCI being the USA supporter for the monograph and the Information Bulletins on the Survey of Chemicals Being Tested for Carcinogenicity. This bulletin is a listing of chemicals being tested in laboratories throughout the world. Under the Cooperative Agreement, NCI:

a. Makes suggestions to IARC on types of chemicals that should be evaluated at the three planned working group meetings per held in Lyon, France.

b. Makes suggestions and gives assistance to IARC as to USA resource people who should attend and participate in Working Group meetings. Personnel from regulatory agencies and trade associations should attend as observers.

3. Program Involvement in Relation to Input from NCI

Under the section on scientific resources, reference was made to NCI input as to data on production, occurrence, analysis, and use of chemicals. NCI, also provides information relevant to carcinogenicity on chemicals tested in U.S. laboratories. These data are then incorporated in the Information Bulletin on the Survey of Chemicals Being Tested for Carcinogenicity.

In discussing certain phases of work that involve assistance and collaboration on the part of NCI with IARC, reference was made to the essentiality of effective liaison and support. Participation by the NCI Program Director in the working group meetings in Lyon, France could be either as an observer or as a representative of NCI or as a full member of the working group in his personal capacity as a scientist.

4. Reporting Requirements

NCI wishes to continue a semi-annual reporting requirement with scheduling or due dates for reports worked out by mutual agreement between NCI staff and the IARC principal investigators. The volumes of monographs, supplements and survey bulletins are actually exhibits of achievements and accomplishment. Consequently, the semi-annual reports should dwell on planning, participation, selection of chemicals, problems of interfacing and cooperation and logistical matters. In addition, an annual report to be included in the required continuation applications should reflect that the project continues to conform to the purposes, objectives and conditions of the award and has substantial programmatic involvement by NCI with the performer of the project.

5. Publication and Distribution

One of the significant features of the IARC project in development of this international authoritative reference source is the publication and distribution, on a world-wide basis, of these volumes, including the supplements to the volumes listing Chemicals and Industrial Processes Associated with Cancer in Humans, as well as the Survey Bulletins.

The National Cancer Institute will receive approximately 400 copies of each volume published. The NCI distributes these copies to NCI staff, representatives of other agencies interested in environmental and occupational carcinogenesis, selected university scientist engaged in carcinogenesis research, public health organizations and medical libraries. Therefore, many organizations and scientists in the USA and abroad benefit from this program, which is partially supported by the National Cancer Institute.

The following administrative terms also apply:

INFORMATION: NCI staff have determined that the application as submitted is within the approved scope of work. This non-competing award has been made at a level based on the amounts indicated in the previous Notice of Grant Award, as adjusted per National Cancer Institute's implementation of the NIH Fiscal Year 2012 funding policy. Funds may be rebudgeted between direct costs and F&A costs, consistent with the applicable cost principles for the grantee organization, institutional requirements for prior approval and NIH policy requirements for prior approval.

INFORMATION : This award has been issued in accordance with the NIH Fiscal Year 2012 funding policy for non-competing awards, as described in NIH Guide for Grants and Contracts Notice NOT-OD-12-036 (<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-12-036.html>). If applicable, the support recommended for future years has also been adjusted consistent with the referenced notice.

INFORMATION: For administrative and grants management concerns, contact Jennifer Meininger at (301) 443-9893 or meiningerjs@mail.nih.gov.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Jacquelyn Boudjeda
Email: boudjedaj@mail.nih.gov **Phone:** 301-496-1204 **Fax:** 301-496-8601

Program Official: Donald G. Blair
Email: db471b@nih.gov **Phone:** 301-496-7028 **Fax:** 301-402-1037

SPREADSHEET SUMMARY
GRANT NUMBER: 5U01CA033193-31

INSTITUTION: INTERNATIONAL AGENCY FOR RES ON CANCER

Budget	Year 31	Year 32	Year 33
Salaries and Wages	\$392,840	(b)(5)	
Fringe Benefits	\$130,949		
Consultant Services	\$42,091		
Travel Costs	\$2,271		
Other Costs	\$149,852		
TOTAL FEDERAL DC	\$718,003		
TOTAL FEDERAL F&A	\$115,598		
TOTAL COST	\$833,601		

Facilities and Administrative Costs	Year 31	Year 32	Year 33
F&A Cost Rate 1	16.1%	(b)(5)	
F&A Cost Base 1	\$718,003		
F&A Costs 1	\$115,598		

Progress Report Scanning Cover Sheet

5U01CA033193-31

PI Name: **STRAIF, KURT**
Org: **INTERNATIONAL AGENCY FOR RES ON
CANCER**
Start Date: **09/01/2012**
Snap: **N/A (NEEDS TO BE BOOKMARKED)**
Appl ID: **8327020**
Rec'd
Date: **07/11/2012**

Department of Health and Human Services
Public Health ServicesReview Group
ZCA1RPRB7J1Type
5Activity
U01Grant Number
5U01CA033193-30 REV. -31**Grant Progress Report**

Total Project Period

From: 09/01/1985

Through: 08/31/2015

Requested Budget Period

From: 09/01/2012

Through: 08/31/2013

1. TITLE OF PROJECT

Evaluation of Carcinogenic Risks to Humans

2a. PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR

(Name and address, street, city, state, zip code)

Kurt Straif

IARC Monographs Section

International Agency for Research on Cancer

150, Cours Albert Thomas

F-69372 Lyon cedex 08, France

2b. E-MAIL ADDRESS

straif@iarc.fr

2c. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT

IARC Monographs Section

2d. MAJOR SUBDIVISION

IARC Monographs Section

2e. Tel: 33-4-72.73.85.07

Fax: 33-4-72.73.83.19

3a. APPLICANT ORGANIZATION

(Name and address, street, city, state, zip code)

International Agency for Research on Cancer

150, Cours Albert Thomas

F-69372 Lyon cedex 08, France

3b. Tel: 33-4-72.73.84.85

Fax: 33-4-72.73.85.75

3c. DUNS: 279551881

4. ENTITY IDENTIFICATION NUMBER

1900210016A1

JUL 11 2012

6. HUMAN SUBJECTS

 No Yes

6a. Research Exempt

 No YesIf Exempt ("Yes" in 6a):
Exemption No.If Not Exempt ("No" in 6a):
IRB approval date

5. NAME, TITLE AND ADDRESS OF ADMINISTRATIVE OFFICIAL

Olaf Kelm, External Relations Officer, International Agency for Research on Cancer, 150 Cours Albert Thomas, F-69372 Lyon cedex 08, France

6b. Federal Wide Assurance No. 00005058

Tel: 33-4-72.73.84.94

Fax: 33-4-72.73.85.64

6c. NIH-Defined Phase III

Clinical Trial No Yes

E-MAIL: igo@iarc.fr

7. VERTEBRATE ANIMALS

 No Yes

7a. If "Yes," IACUC approval Date

10. PROJECT/PERFORMANCE SITE(S)

Organizational Name: Applicant

7b. Animal Welfare Assurance No.

DUNS:

8. COSTS REQUESTED FOR NEXT BUDGET PERIOD

8a. DIRECT \$732,363

8b. TOTAL \$850,273

Street 1:

Street 2:

9. INVENTIONS AND PATENTS

 No YesIf "Yes," Previously Reported Not Previously Reported

City:

County:

State:

Province:

Country:

Zip/Postal Code:

Congressional Districts:

11. NAME AND TITLE OF OFFICIAL SIGNING FOR APPLICANT ORGANIZATION (Item 13)

Christopher P. Wild, Director

TEL: 33-4-72.73.85.77

FAX: 33-4-72.73.85.64

E-MAIL: director@iarc.fr

12. Corrections to Page 1 Face Page

13. APPLICANT ORGANIZATION CERTIFICATION AND ACCEPTANCE: I certify that the statements herein are true, complete and accurate to the best of my knowledge, and accept the obligation to comply with Public Health Services terms and conditions if a grant is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties.

SIGNATURE OF OFFICIAL NAMED IN

11. (In ink)

PP
Silvia Franck

DATE

3 July 2012

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

DETAILED BUDGET FOR NEXT BUDGET PERIOD – DIRECT COSTS ONLY	FROM 09/01/2012	THROUGH 08/31/2013	GRANT NUMBER 5U01CA033193-30 REV.
---	---------------------------	------------------------------	---

List PERSONNEL (*Applicant organization only*)
 Use Cal, Acad, or Summer to Enter Months Devoted to Project
 Enter Dollar Amounts Requested (*omit cents*) for Salary Requested and Fringe Benefits

NAME	ROLE ON PROJECT	Cal. Mnths	Acad. Mnths	Summer Mnths	SALARY REQUESTED	FRINGE BENEFITS	TOTALS
STRAIF, K.	PD/PI	(b)(4), (b)(6)			0	0	0
EL-GHISSASSI, F.	Scientist				82,155	27,385	109,540
BENBRAHIM-TALLAA, L.	Scientist				88,272	29,424	117,696
BOUVARD, V.	Scientist				85,436	28,478	113,914
To be named	Scientist	10			92,341	30,780	123,121
EGRAZ, S.	Archivist	(b)(4), (b)(6)			59,107	19,702	78,809
RUSSELL, D. * (see note 1 on page 3)	Typist				24,134	8,045	32,179
SUBTOTALS →					431,445	143,814	575,259

CONSULTANT COSTS		
EQUIPMENT (<i>Itemize</i>)		
SUPPLIES (<i>Itemize by category</i>)		
TRAVEL One trip of PI to USA for a scientific meeting and to consult with NCI program officials		2,100
INPATIENT CARE COSTS		
OUTPATIENT CARE COSTS		
ALTERATIONS AND RENOVATIONS (<i>Itemize by category</i>)		
OTHER EXPENSES (<i>Itemize by category</i>) See page 3		155,004
SUBTOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD		\$ 732,363
CONSORTIUM/CONTRACTUAL COSTS	DIRECT COSTS	
CONSORTIUM/CONTRACTUAL COSTS	FACILITIES AND ADMINISTRATIVE COSTS	
TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD (<i>Item 8a, Face Page</i>)		\$ 732,363

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

BUDGET JUSTIFICATION

GRANT NUMBER
5U01CA033193-30 REV.

Provide a detailed budget justification for those line items and amounts that represent a significant change from that previously recommended. Use continuation pages if necessary.

OTHER:

- Working group Feb-13 Volume 107 (\$67,000 X 1)	\$ 67,000
- Working group Jun-13 Volume 108 (\$67,000 X 1)	\$ 67,000
- Printing of Monographs Volume (\$20,000 X 1)	\$ 20,000
- Books, journals and reproduction costs	\$ 1,004

	\$155,004

Note 1 to detailed budget: only (b) (4) of D. Russell's salary is anticipated to be charged to the grant.

CURRENT BUDGET PERIOD	FROM	THROUGH
	09/01/2011	08/31/2012

Explain any estimated unobligated balance (including prior year carryover) that is greater than 25% of the current year's total budget.

	Total estimated expenditure	Estimated unobligated balance
	-----	-----
DIRECT COSTS	\$718,002	\$0
INDIRECT COSTS	\$115,598	\$0
	-----	-----
TOTAL COSTS	\$833,600	\$0

For New and Renewal Applications (PHS 398) – DO NOT SUBMIT UNLESS REQUESTED
For Non-competing Progress Reports (PHS 2590) – Submit only Active Support for Key Personnel

PHS 398/2590 OTHER SUPPORT

Provide active support for all key personnel. **Other Support includes all financial resources, whether Federal, non-Federal, commercial or institutional, available in direct support of an individual's research endeavors, including but not limited to research grants, cooperative agreements, contracts, and/or institutional awards.** Training awards, prizes, or gifts do not need to be included.

There is no "form page" for other support. Information on other support should be provided in the *format* shown below, using continuation pages as necessary. **Include the principal investigator's name at the top and number consecutively with the rest of the application.** The sample below is intended to provide guidance regarding the type and extent of information requested.

For instructions and information pertaining to the use of and policy for other support, see Other Support in the PHS 398 Part III, Policies, Assurances, Definitions, and Other Information.

Note effort devoted to projects must now be measured using person months. Indicate calendar, academic, and/or summer months associated with each project.

Format

NAME OF INDIVIDUAL

ACTIVE/PENDING

Project Number (Principal Investigator) Source Title of Project (or Subproject)	Dates of Approved/Proposed Project Annual Direct Costs	Person Months (Cal/Academic/ Summer)
The major goals of this project are...		

OVERLAP (summarized for each individual)

BAAN, R.

ACTIVE

(b)(4), (b)(6) (Baan)

1/1/2011 – 12/31/2011 (b)(4), calendar

(b)(4), (b)(6)

53,100 euros D.C. (\$65,963) (b)

IARC Monographs Programme 2011

The major goals of this project are to support, in part, a third volume of IARC Monographs each year.

(b)(4), (b)(6) (Baan)

1/1/2012 – 12/31/2012 (b)(4), calendar

(b)(4), (b)(6)

53,100 euros D.C. (\$65,963) (b)

IARC Monographs Programme 2012

The major goals of this project are to support, in part, a third volume of IARC Monographs each year.

PENDING

None.

OVERLAP

None.

STRAIF, K.

BENBRAHIM-TALLAA, L.

BOUVARD, V.

EL-GHISSASSI, F.

GROSSE, Y.

GUHA, N.

LAUBY, B.

There are no other active or pending sources of support for the key scientists on the IARC Monographs project.

Program Director/Principal Investigator (Last, First, Middle): STRAIF, Kurt

PROGRESS REPORT SUMMARY	GRANT NUMBER 5U01CA033193-30 REV.	
	PERIOD COVERED BY THIS REPORT	
PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR STRAIF, Kurt	FROM 1 September 2011	THROUGH 31 August 2012
APPLICANT ORGANIZATION International Agency for Research on Cancer		
TITLE OF PROJECT (Repeat title shown in Item 1 on first page) Evaluation of Carcinogenic Risks to Humans		
A. Human Subjects (Complete Item 6 on the Face Page)		
Involvement of Human Subjects	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
B. Vertebrate Animals (Complete Item 7 on the Face Page)		
Use of Vertebrate Animals	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
C. Select Agent Research	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
D. Multiple PD/PI Leadership Plan	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change
E. Human Embryonic Stem Cell Line(s) Used	<input checked="" type="checkbox"/> No Change Since Previous Submission	<input type="checkbox"/> Change

SEE PHS 2590 INSTRUCTIONS.

WOMEN AND MINORITY INCLUSION: See PHS 398 Instructions. Use Inclusion Enrollment Report Format Page and, if necessary, Targeted/Planned Enrollment Format Page.

A. Specific Aims

The aim of the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans is to critically review and evaluate the published scientific evidence on carcinogenic hazards to which humans are exposed. These include chemicals, complex mixtures, physical agents, biological agents, occupational exposures, and lifestyle factors. International, interdisciplinary Working Groups of expert scientists develop the critical reviews and evaluations, which are published in the IARC Monographs series.

B. Studies and Results

IARC convened meetings to develop three new volumes of Monographs (Vol. 103-105) and one workshop as a follow-up of Volume 100. IARC is preparing for a second follow-up workshop and three Monographs meetings (Volumes 106-108) that will be convened during the next budget period (1 Sept. 2012 to 31 Aug. 2013). IARC has also finished publishing the pre-Volume 100 Monographs and has published Volumes 100A-F on-line. The printed copies will soon be available, both as individual volumes and as a box-set. Volumes 100A-F have updated the Monographs on the more than 100 agents that had been classified as carcinogenic to humans (Group 1) in Volumes 1-99. Volume 101 is now also available on-line.

Volume103: Bitumens and their emissions, and some heterocyclic aromatic hydrocarbons, 11-18 Oct. 2011

A Working Group (WG) convened in October 2011 to evaluate bitumens and their emissions. Based on the available literature, the WG evaluated 3 classes of bitumen: straight-run bitumens (Class 1), used primarily for road paving, oxidized bitumens (Class 2), used primarily for roofing, and mastic asphalt, used for specialized applications. Epidemiological studies provided limited evidence for an increased risk of lung cancer in workers exposed to oxidized bitumens and to mastic asphalt, but data were inadequate for Class 1 bitumens. Carcinogenicity bioassays were inadequate for Class 1 bitumens, and provided limited evidence

of carcinogenicity for Class 2. There was strong evidence of mutagenic and genotoxic effects in workers exposed to straight-run bitumen emissions. As a result, straight-run bitumen and mastic asphalt and their emissions were classified in Group 2B and oxidized bitumen and their emissions were evaluated as Group 2A.

Volume 104: Polyomaviruses (SV40, BK, JC, and Merkel cell viruses) and malaria, 7-14 February 2012

In Feb. 2012, a WG evaluated several polyomaviruses and malaria. BKV and JCV are highly prevalent in humans worldwide and are responsible for lethal non-cancerous diseases in immuno-suppressed individuals. Based on sufficient evidence in experimental animals and inadequate evidence in humans, both were classified in Group 2B. An etiological role of MCV for a rare human skin cancer, Merkel cell carcinoma, is supported by a few case-control studies, several case-series and strong mechanistic data, which led to a Group 2A evaluation. In the 1950s and early 1960s, millions of people received simian virus SV40-contaminated polio-virus vaccines. SV40 is highly tumourigenic in rodents, but the extensive data available did not provide compelling evidence that SV40 infects humans and it was classified in Group 3. "Malaria caused by infection with *Plasmodium falciparum* in holoendemic areas" was classified in Group 2A based on limited epidemiological evidence that malaria is associated with endemic Burkitt lymphoma (eBL), and strong mechanistic evidence that *P. falciparum* can disturb the immature immune system in young children and reactivate the ubiquitous Epstein-Barr virus, a necessary agent for eBL.

Volume 105: Diesel and gasoline engine exhausts and some nitroarenes (5-12 June 2012)

In June 2012, a WG reviewed the carcinogenicity of diesel and gasoline engine exhausts. Diesel engine exhaust was classified as carcinogenic to humans (Group 1), based on sufficient evidence that exposure is associated with an increased risk for lung cancer. The WG also noted a positive association (limited evidence) with an increased risk of bladder cancer. The WG concluded that gasoline exhaust was possibly carcinogenic to humans (Group 2B). The evaluation of ten nitroarenes led to mechanistic upgrades of 3-nitrobenzanthrone to Group 2B, and of 1-nitropyrene and 6-nitrochrysene to Group 2A; the Group 2B classification of the other seven nitroarenes was re-affirmed.

Workshop on Volume 100: Tumour concordance and mechanisms of carcinogenesis: lessons learned from Volume 100 of the IARC Monographs, 16-18 April 2012

As a follow-up to Volume 100, two Workshops are organized on "Tumour concordance between humans and experimental animals" and "Mechanisms involved in human carcinogenesis". Complete databases, capturing animal cancer data and mechanistic information from Volume 100, are in preparation. The first Workshop fine-tuned the animal cancer database, and proposed an outline for the database on mechanisms. Separate and combined analyses of these databases will be discussed at the second Workshop, in Nov. 2012.

The full text of all *Monographs* is freely available on <http://monographs.iarc.fr/>. All volumes published since Volumes 46 (1989) and Supplement 7 are now available, as well as the summary sections of Volumes 1 – 45.

D. Plans. During the next budget period, IARC will convene three expert WG and one Workshop.

Vol. 106: Trichloroethylene and some chlorinated agents (2-9 Oct. 2012)

Vol. 107: Polychlorinated biphenyls and polybrominated biphenyls (12-19 Feb. 2013)

Vol. 108: Agents to be announced soon at <http://monographs.iarc.fr/ENG/Meetings/index.php> (4-11 June 2013)

2nd Workshop on Volume 100 (28-30 Nov. 2012): These workshops will help to increase understanding of the correspondence across species, facilitate joint consideration of agents that act through similar mechanisms, identify biomarkers that could be influential in future studies, identify susceptible populations and developmental stages and promote research that will lead to more confident evaluations.

IARC will also focus attention on checking Vol. 102-105 and preparing them for publication and will continue making the full text of all Monographs freely available. Further dissemination improvements will include: a) completion of a fully searchable relational database of Monograph results, enabling complex queries, and linking to other IARC databases (IARC Blue Books, Globocan, etc); b) development of ePub format of Monographs for delivery to e-book readers and tablets.

E. Publications

- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100A, A Review of Human Carcinogens: Pharmaceuticals. IARC, Lyon, published on-line:
<http://monographs.iarc.fr/ENG/Monographs/vol100A/index.php>
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100B, A Review of Human Carcinogens: Biological Agents. IARC, Lyon, published on-line:
<http://monographs.iarc.fr/ENG/Monographs/vol100B/index.php>
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100C, A Review of Human Carcinogens: Arsenic, Metals, Fibres, and Dusts, published on-line:
<http://monographs.iarc.fr/ENG/Monographs/vol100C/index.php>
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100D, A Review of Human Carcinogens: Radiation. IARC, Lyon, published on-line:
<http://monographs.iarc.fr/ENG/Monographs/vol100D/index.php>
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100E, A Review of Human Carcinogens: Personal Habits and Indoor Combustions. IARC, Lyon, published on-line:
<http://monographs.iarc.fr/ENG/Monographs/vol100E/index.php>
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 100F, A Review of Human Carcinogens: Chemical Agents and Related Occupations. IARC, Lyon, published on-line:
<http://monographs.iarc.fr/ENG/Monographs/vol100F/index.php>
- IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 101, Some Chemicals in Industrial and Consumer Products, Food Contaminants and Flavourings, and Water Chlorination By-Products. IARC, Lyon, published on-line:
<http://monographs.iarc.fr/ENG/Monographs/vol101/index.php>
- Baan RA, Coglianò VJ. The IARC Monographs Programme: Cancer Hazard Identification as a First Step in Cancer Risk Assessment and Cancer Prevention. In: Obe G, Jandrig B, Marchant GE, Schütz H & Wiedemann PM eds. Cancer Risk Evaluation: Methods and Trends. Wiley-VCH Verlag GmbH & Co., 2011, pp. 41-60.
- Benbrahim-Tallaa L, Baan RA, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Guha N, Loomis D, Straif K, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. Diesel and gasoline engine exhausts and some nitroarenes. *Lancet Oncol* (E-pub ahead of print: DOI:10.1016/S1470-2045(12)70280-2)
- Bouvard V, Baan R, Grosse Y, Lauby-Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Straif K, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of malaria and of some polyomaviruses. *Lancet Oncol*. 2012; 13: 339-340
- Camargo C, Stayner LT, Straif K, Reina M, Al-Alem U, Demers PA, Landrigan PJ. Occupational exposure to asbestos and risk of ovarian cancer: a meta-analysis. *Env. Health Perspect*. 2011; 119: 1211-1217
- Coglianò VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Wild CP. Preventable exposures associated with human cancers. *J Natl Cancer Inst* 2011; 103: 1827-1839
- Demetriou C, Straif K, Vineis P. From testing to estimation: the problem of false positives in the context of carcinogen evaluation in the IARC Monographs. *Cancer Epidemiol Biom Prev*. E-pub ahead of print: doi:10.1158/1055-9965.EPI-12-0276
- Guha N, Straif K, Benbrahim-Tallaa L. The IARC Monographs on the carcinogenicity of crystalline silica. *Med. Lav*. 2011; 102: 310-320
- Lauby-Secretan B, Baan R, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Galichet L, Straif K, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. Bitumens and bitumen emissions, and some heterocyclic polycyclic aromatic hydrocarbons. *Lancet Oncol* 2011; 12: 1190-1191

Program Director/Principal Investigator (Last, first, middle): STRAIF, Kurt

GRANT NUMBER
5U01CA033193-30 REV.

CHECKLIST

1. PROGRAM INCOME (See instructions.)

All applications must indicate whether program income is anticipated during the period(s) for which grant support is requested. If program income is anticipated, use the format below to reflect the amount and source(s).

Budget Period	Anticipated Amount	Source(s)

2. ASSURANCES/CERTIFICATIONS (See instructions.)

In signing the application Face Page, the authorized organizational representative agrees to comply with the policies, assurances and/or certifications listed in the application instructions when applicable. Descriptions of individual assurances/certifications are provided in Part III of the PHS 398, and listed in Part I, 4.1 under Item 14. If unable to certify compliance, where applicable, provide an explanation and place it after the Progress Report (Form Page 5).

3. FACILITIES AND ADMINISTRATIVE (F&A) COSTS

Indicate the applicant organization's most recent F&A cost rate established with the appropriate DHHS Regional Office, or, in the case of for-profit organizations, the rate established with the appropriate PHS Agency Cost Advisory Office.

F&A costs will *not* be paid on construction grants, grants to Federal organizations, grants to individuals, and conference grants. Follow any additional instructions provided for Research Career Awards, Institutional National Research Service Awards, Small Business Innovation Research/Small Business Technology Transfer Grants, foreign grants, and specialized grant applications.

DHHS Agreement dated: 08/11/2010 No Facilities and Administrative Costs Requested.

No DHHS Agreement, but rate established with _____ Date _____

CALCULATION*

Entire proposed budget period: Amount of base \$ 732,363 x Rate applied 16.10 % = F&A costs \$ 117,910

Add to total direct costs from Form Page 2 and enter new total on Face Page, Item 8b.

*Check appropriate box(es):

Salary and wages base Modified total direct cost base Other base (Explain)

Off-site, other special rate, or more than one rate involved (Explain)

Explanation (Attach separate sheet, if necessary.):

Base is total direct costs.

ALL PERSONNEL REPORT

GRANT NUMBER
5U01CA033193-29 REV.

Place this form at the end of the signed original copy of the application. Do not duplicate.

Always list the PD/PI(s). In addition, list all other personnel who participated in the project during the current budget period for at least one person month or more, regardless of the source of compensation (a person month equals approximately 160 hours or 8.3% of annualized effort). Use the following abbreviated categories for describing Role on Project:

- PD/PI
- Co-Investigator
- Faculty Collaborator
- Staff Scientist (doctoral level)
- Postdoc (Postdoctoral Scholar, Fellow, or Other Postdoctoral Position)
- Grad Rsch Asst (Graduate Research Assistant)
- Undergrad Rsch Asst (Undergraduate Research Assistant)
- Rsch Asst (Research Assistant/Coordinator)
- Technician
- Consultant
- Biostatistician
- Other (Specify)

If personnel are supported by a Reentry or Diversity Supplement or American Recovery and Reinvestment Act (ARRA) funding, please indicate such after the Role on Project, using the following abbreviations: RS - Reentry Supplement; DS - Diversity Supplement; AF - General ARRA Supplement; ASE - ARRA Summer Experience funding.

Use Cal (calendar), Acad, or Summer to enter months devoted to project.

Commons ID	Name	Degree(s)	SSN (last 4 digits)	Role on Project	DoB (MM /YY)	Cal	Acad	Summer
k.straif	Straif, Kurt	MD, PhD	N/A	Principal Invest.	(b)(6)	(b)(4), (b)(6)		
	Baan, Robert	PhD	N/A	Co-Investigator				
	Benbrahim-Tallaa, Lamia	PhD	(b)	Staff Scientist				
	Bouvard, Véronique	PhD	N/A	Staff Scientist				
	Egraz, Sandrine	BA	N/A	Other (Archivist)				
	Elbers, Elisabeth	MA	N/A	Technician				
	El-Ghissassi, Fatiha	PhD	N/A	Staff Scientist				
	Galichet, Laurent	MS	N/A	Other (Editor) until 31 Oct. 2011				
	Grosse, Yann	PhD	N/A	Staff Scientist				
	Guha, Neela	PhD	(b)	Staff Scientist				
	Kajo, Brigitte	N/A	N/A	Technician				
	Lauby-Secretan, Béatrice	PhD	N/A	Staff Scientist				
	Lorenzen-Augros, Helene	BA	N/A	Other (Secretary)				
	Russell, Dorothy	BA	N/A	Other (Typist)				

International Agency for Research on Cancer



**World Health
Organization**

150 cours Albert Thomas
69372 Lyon cedex 08, France

Section of IARC Monographs
Tel.: +33 4 72 73 85 07
Fax: +33 4 72 73 83 19
E-mail: imo@iarc.fr
<http://monographs.iarc.fr>

Division of Extramural Activities
Support, OER
National Institutes of Health
6705 Rockledge Drive, Room 2207,
MSC 7987
Bethesda, MD 20817
USA

Special courier: tel. 1-301-594.6584

Ref.: IMO/43/4

29 June 2012

Grant No 5U01CA033193-30 REVISED

Dear Sirs,

I enclose our Grant Progress Report for the budget period from 1 September 2011 to 31 August 2012, including the budget request of the next period from 1 September 2012 to 31 August 2013.

No biosketches are included, as there are no new staff members working on the project since our last progress report.

I trust the enclosed report is satisfactory and look forward to our continued collaboration.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'K. Straif', written over a horizontal line.

Kurt Straif, MD, PhD
Head, IARC Monographs Section

ENCL: As mentioned